# Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

> **NCT04473859** · PHASE1 · COMPLETED · sponsor: **Xequel Bio, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Wound Heal

## Interventions

- **DRUG:** FSR Peptide 20μM
- **DRUG:** FSR Peptide 50μM
- **DRUG:** FSR Peptide 100μM
- **DRUG:** FSR Peptide 200μM
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04473859
- **Lead sponsor:** Xequel Bio, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03-06
- **Primary completion:** 2009-04-28
- **Final completion:** 2009-04-28
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04473859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04473859, "Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04473859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*